Specialties

Targeted Oncology | Dialogues in Diagnostics
Targeted Oncology | Differential Diagnosis
Targeted Oncology | Case-Base Peer-Perspective

Top Medical News Today

Frontline Myeloma Therapies Undergoing Dramatic Transformation
The high level of efficacy observed with the combination of bortezomib, lenalidomide, and dexamethasone in the phase III SWOG S0777 study significantly changed the frontline treatment paradigm for patients with multiple myeloma.
Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering, discusses what is on the horizon for the use of PD-L1 agents in liver cancer.
Despite Skepticism, Immunotherapy Has Early Promise in GI Cancer
Precision oncology should play a vital role in the shift toward value-based medicine by helping to deliver more effective therapies with more manageable pricing profiles.
 Targeted Treatments, Immunotherapy Options Expanding in HCC
A number of novel therapies are currently being explored as second-line treatments for patients with advanced hepatocellular carcinoma, including a host of targeted therapies and various immune checkpoint inhibitors.
Shortcomings in SIRFLOX Design May Have Skewed PFS Findings
Navesh K. Sharma, DO, PhD, discusses the addition of Yttrium-90 resin microspheres to standard frontline FOLFOX-based chemotherapy with or without bevacizumab in patients with liver metastatic colorectal cancer.
Moving Toward a Cure With Immunotherapy
By working together, the potential for clinical benefit in patients with cancer is increasingly bright.
View More >

Features

Nivolumab Produces Robust 5-Year OS Rates in Melanoma
Nivolumab Produces Robust 5-Year OS Rates in Melanoma
Single-agent nivolumab demonstrated a robust 5-year overall survival rate of 34% for heavily pretreated patients with metastatic melanoma.
Exploration Into Stereotactic Body Radiation Therapy for Pancreatic Cancer
New technology and improvements in administration techniques could make stereotactic body radiation therapy easier and more plausible for patients with pancreatic cancer.
Benefits Observed with Second-Line Therapy in Metastatic Pancreatic Cancer
Second-line treatment of metastatic pancreatic cancer, after first-line treatment with nab-paclitaxel plus gemcitabine or gemcitabine alone, is feasible and may improve outcomes.
Trabectedin Boosts PFS Over Dacarbazine in Uterine Leiomyosarcoma
A phase II studyshowed the immunomodulatory agent lenalidomide significantly increased progression free survival in patients with relapsed or refractory mantle cell lymphoma.
Liposomal Irinotecan Combo Added to NCCN Guideline for Pancreatic Cancer in Second-Line
Liposomal irinotecan, fluorouracil, and leucovorin in combination has been added to the 2016 NCCN Clinical Practice Guidelines in Oncology as a second-line treatment for patients with gemcitabine-refractory metastatic pancreatic cancer.
Publications